Ladies and gentlemen, good afternoon, thank you for standing by and welcome to the Intuitive Surgical Quarter One 2013 Earnings Release Conference Call. At this time all lines are in a listen-only mode. There will be an opportunity for your questions and instructions will be given at that time. (Operator Instructions) And as a reminder today’s conference is being recorded. I would now like to turn the conference over to our host Senior Director of Finance, Mr. Calvin Darling. Please go ahead.

Thank you, good afternoon and welcome to Intuitive Surgical’s first quarter earnings conference call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Aleks Cukic, our Vice President of Strategic Planning. Before we begin, I would like to inform you that comments mentioned on today’s call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the Company’s Securities and Exchange Commission filings. Prospective investors are cautioned not to place undue reliance on such forward-looking statements. Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archive section under our Investor Relations page. In addition, today’s press release has been posted to our website. Today’s format will consist of providing you with highlights of our first quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter’s business and operational highlights. Marshall will provide a review of our first quarter financial results. Aleks will discuss marketing and clinical highlights. Then I will provide an update to our financial forecast for 2013, and finally we will host a question-and-answer session. With that, I will turn it over to Gary.

Thank you for joining us today. Before we get started describing our quarterly performance, I’d like to make a few comments regarding current events. As you know, we are in the midst of a concerted effort by critics of robotic surgery, to challenge the benefited range of patients, the value it brings to the medical community and the quality of our organization. While taking these allegations very seriously, we remain deeply committed to developing and providing products that are in the surgeons hands, ease the burden of surgery for patients who can benefit from them. We take pride in the benefits provided by our systems, demonstrated a numerous large scale population studies comparing da Vinci surgery to open surgery for several different procedures. We are confident that those who invest their time in a serious review of the clinical literature on da Vinci will find ample evidence, and the benefit it brings to patients, surgeons, hospitals, and the medical community of ours. Turning to our performance in the quarter, we experienced strong growth in general surgery, slower growth in gynecology and return to stability in urology. This resulted in an 18% procedure growth over 2012. The first quarter of 2013 had one fewer surgery day than 2012, taking this into account normalized procedure growth improves to approximately 20%. General surgery growth was led by Single-Site Cholecystectomy and colorectal procedures. Gynecologic procedures for benign indications are typically seasonally slow in the first quarter. However, we’ve experienced slower than expected growth into benign Hysterectomy in this first quarter of 2013. Worldwide urology procedures experienced solid growth aided by the stabilizing of prostatectomy procedures in the United States. Considering the above procedure growth for the quarter came in it at the lower range of our expectations. Aleks will provide additional procedure commentary later…

Thank you, Gary. Our first quarter revenue was $611 million, up 23% compared with $495 million for the first quarter of 2012 and roughly equal to the $609 million last quarter. First quarter revenues by product category were as follows. First quarter instrument and accessory revenue was $261 million, up 26% compared with $208 million for the first quarter of 2012 and up 3% compared with $254 million in the fourth quarter of 2012. The year-over-year increase in instrument and accessory revenue was driven by procedure growth of 18%. Sales of new products including Single Site, Vessel Sealer, and Firefly, and higher stocking orders associated with higher system unit sales. The 18% procedure growth was impacted by one additional operating day in the first quarter of 2012 reflecting leap year. Excluding the impact of leap year, procedure growth would have been approximately 20%. Procedure growth also reflects seasonality associated with the benign hysterectomies, which was more pronounced in 2013 compared with 2012 as we achieve deeper penetration in this market. The year-over-year procedure growth was led by U.S. general surgery and gynecology procedures, partially offset by lower U.S. dVPs of approximately a 11%. U.S. dVP procedures are approximately 4% higher than the fourth quarter of 2012. The sequential increase in instrument and accessory revenue compared with the last quarter was driven by the timing of customer orders and new product revenue associated with the increased usage from Firefly, Vessel Sealer, and Single Site. Instrument and accessory revenue realized per procedure including initial stocking orders was approximately $2,110 per procedure, which is higher than the $1,990 realized in the first quarter of last year, and the $2,050 realized in the fourth quarter. The sequential increase from the fourth quarter of 2012 to the first quarter of 2013 was driven primarily by…

Thank you, Marshall. During the first quarter, we sold 164 da Vinci systems; 115 in the United States, 16 into Europe, and 33 into rest of world markets. As part of the 164 system sales, 9 standard da Vinci systems and 30 da Vinci S systems were traded in for credit against sales for new da Vinci Si systems. We finished the quarter with a net 125 system additions to the installed base bringing to 2,710, the cumulative number of da Vinci systems worldwide; 1,957 in the United States, 430 in Europe, and 323 in rest of world markets. 75 of the 164 systems installed during the quarters represented repeat system sales to existing customers. In total 162 of the 164 systems sold represented da Vinci Si or SIE systems, which included 48 dual console systems. The 49 systems, systems sales internationally included 25 into Japan, 4 into France, and 3 into Turkey. Clinically, Q1 year-over-year procedure growth was approximately 18%, led by the category of general surgery, followed by GYN. General surgery growth was paced by cholecystectomy, followed by colon and rectal resections. As Gary stated, procedure growth reflected seasonality, the reduction of selling days and a slower quarter for benign dVH. dVP more specifically the rate of decline for U.S. dVP, a topic extensively discussed, appears to be flattening out. U.S. dVP was once again up on a sequential basis with a reduced rate of decline as compared to last year. Overall, other urology, as well as international dVP showed solid growth both on a sequential and on a year-over-year basis. Recently released new products continue to perform well, notably Single-Site where customer feedback has been positive and sales have remained strong. Through Q1 2013, we have sold Single-Site instrument and accessory kits to approximately 630 U.S. customers.…

Thank you, Aleks. I will be providing you with an update to our financial forecast for 2013, including procedures, revenues, and other elements of the income statement on a GAAP basis. I will also provide estimates of significant non-cash expenses to provide you with visibility into our expected future cash flows. Starting with procedures; on our last call, we projected our full-year 2013 procedures to growth approximately 20% to 23% from the base of approximately 450,000 procedures performed in 2012. Now based upon first quarter procedure trends, we expect our full-year 2013 procedure growth to be in the lower-end of that range. Moving on to revenues. Last quarter, we forecasted full-year 2013 revenue growth of between 16% and 19%. Based upon favorable new instrument and accessory product sales and utilization, we now expect full-year 2013 revenue growth at the higher end of that range. Our first quarter system ASP of $1.55 million was higher than we expected, reflecting a high proportion of dual console configurations in the system mix. Going forward in 2013, we would expect our systems product mix and overall systems ASP to return towards historical 2012 levels. Now turning to operating income. We continue to expect full-year operating income to fall within a range of between 38% and 39% of net revenue. Our first quarter operating margin of 41% reflected favorable system pricing and timing of operating expenses. In Q2, we would expect operating expenses to increase at least $15 million, reflecting higher variable compensation, prototype, headcount, stock compensation and legal expenses. We continue to expect 2013 stock compensation to total between $184 million and $192 million for the year. Timing of recognition should follow-up quarterly pattern similar to 2012. Amortization of purchased intellectual property which is mostly reported as R&D expense is still expected to come in between $28 million and $30 million in 2013. We continue to expect to other income to total between $18 million and $22 million in 2013. With regard to income tax, as Marshall described, our Q1 tax rate reflected the benefit related to the reinstatement of the 2012 R&D tax credit. For the rest of this year, we continue to anticipate our tax rate to fall within a range of between 28% and 30% of pre-tax income. Our share account for calculating EPS in Q1 2013 was approximately 41.4 million shares. Going forward our share account will depend upon the magnitude and timing of share buybacks. We will continue to be thoughtful in our execution of the 1.2 billion authorized by the Board for that purpose. That concludes our prepared remarks, we will now open the call to your questions. Operator? Evan Lodes – JP Morgan: Hi, guys. This is Evan Lodes in for Tycho. I guess first question was for Gary, can you disaggregate the slowdown in benign dVH between the seasonal effects that you mentioned such as deductibles and then also the more coordinated efforts that you talked about with regards to the roll-off specifically?

I think I heard the question, although there is a little bit of background noise on the call. I think the question was can we disaggregate the benign hysterectomy slowdown. No, I think there are a few things going on there. As we look at multi port benign hysterectomy in total, we think our market opportunity is really the open surgical market share. There is still more than 100,000 open benign hysterectomies being done in the U.S. We see three issues impacting benign hysterectomy. First, as we become a larger part of the market, the impact of seasonality plays a proportionally bigger role in our performance. So, it’s simply when a new technique is for a small part of the market the number of unserved patients is sufficiently large that changes in the total number of patient admissions do not materially impact growth. However, as penetration increases the sensitivity to total admissions increases with it. Second, several large healthcare organizations are reporting a greater than expected decline in patient admissions in the first quarter. Given that benign hysterectomy is a large part of our procedure base, that will impact us as well. Third, negative press has some hard to measure impact on benign hysterectomy, although it doesn’t appear to be large, it’s also probably not zero. Evan Lodes – JP Morgan: Thank you very much. And then the second question, you mentioned the international procedure growth was about 14%, could you help us think about what the growth is in Europe and trends there that you’ve seen recently? Thank you.

Yeah, I mean just numerically, the 14% would be higher on the Asia and rest of world markets and a bit lower on the European side. Evan Lodes – JP Morgan: Thank you very much.

The next question comes from the line of Ben Andrew with William Blair, please go ahead. Benjamin Andrew – William Blair & Company: Hi, good afternoon. Can you hear me?

Hi, Ben.

Yes, we can. Benjamin Andrew – William Blair & Company: Okay. Gary, talk a little bit about the guidance of 20% to 23% and targeting kind of the low end of that range, what does it take for you to hit that 20%, does it require a stabilization in benign dVH and again continued stabilization of prostatectomy, and just maybe walk through how you get to that 20%, because we’re struggling a little bit as we try to plug-in the number for Q1 to get there?

A couple of things and then Calvin may help you a little bit with that as well. But as we look out, we’ve seen three quarters in a row with prostatectomy where it’s sort of finding its footing with regard to the U.S. So we are assuming that that remains -- that trend stays about the same as we go through. General surgery has shown real strength. On benign gynecology, I want to make sure, we’re separating out gynecologic procedures from just hysterectomy. There is more in benign gynecology to just hysterectomy; there is myomectomy, sacrocolpopexy both of which were meeting our expectations in this quarter. The quarter is a little bit hard to interpret just because of the number of operating days and there is little bit of ambiguity as to how many there were in terms of how the holidays played, and we’ll have to see a little bit and impossible to predict the future perfectly. We look out and think that our guidance at the low end makes sense given those, kind of three factors together.

Yeah, and you know as we look at our guidance, there are a lot of moving parts more and more as you realize, but, the key areas of growth are the same as they were entering the year, specifically the number of new procedures coming from U.S. general surgery, U.S. gynecology, and international dVP are going to be still the largest areas of growth. As Gary said, based upon customer and surgeon feedback, we have not seen a major impact on the benign dVH procedure demand, although we can’t really predict where that may head in the future. We expect seasonality to play through and we’ll benefit later in the year on some of these things as well, and we do forecast that dVP has bottomed out. So, I think that’s -- having said that, nobody has a crystal ball and we’ll take it one quarter at a time. Ben Andrew – William Blair & Co. LLC: Okay. And two more quick questions, Gary. Are you hearing additional chatter or kind of disturbing chatter from either surgeons or hospitals questioning the safety and obviously efficacy of the system, and I know that may be hard to quantify, but does it feel different now then it did a month ago, and were there trends in the quarter or something that got your attention?

Ben Andrew – William Blair & Co. LLC: Okay. And then finally, you mentioned something intriguing about SG&A spending, popping up in the second quarter. I thought I heard prototyping in the middle of that list. Can you describe that at all?

. : Ben Andrew – William Blair & Co. LLC: Okay, thank you.

Ben, you had asked a question, just a follow-up on kind of a surgeon’s view or surgeon’s commentary on it, and I’ll tell you one surgeon’s comment to me with regard to some of the criticism that’s been out there. He came back and said, hey, open surgery hasn’t gotten any better for patients and laparoscopy hasn’t gotten any easier for surgeons, and I think that’s true. Ben Andrew – William Blair & Co. LLC: We definitely heard the same thing. Thank you.

Our next question today comes from the line of Lennox Ketner representing Bank of America. Please go ahead. Lennox Ketner – Bank of America: Hi. Can you hear me okay?

Yes

Yes

Great, just a few questions. First, I’m sorry if I missed this, but I think you said that the dVP was down about 11% year-over-year. But last quarter you had provided, I think the overall growth rates for both general surgery and gynecology as well. Is that something you would be willing to breakout at this time?

We do that on an annual basis and not quarterly.

Yeah. So, for starters, while we had the approval last year, the first clinical cases happened in this quarter, and really the reason of it is two-fold. One is, we want to have outstanding first customer experiences with it, so far we have. The second thing is the supply chain for the surgical stapler is a long one, it’s a full system that has electronics in it, software in it, motor packs, and single use sterilizable products. So we want to make sure that that supply chain is exceptionally stable and ready as we move to scale. And it’s really working, those two things in parallel to make sure we get a great result. Stapling is a subtle product. There are a lot of things about it in terms of both its manufacturing and its use that you want to make sure you get right, and so we’ll be doing that. And as we start to see that stability, then we’ll start to ramp the release.

Okay. Just on a feature standpoint, you feel confident that the version that you have now has all the features that it needs to ultimately be successful?

Okay. That’s helpful. And then, last one just on the buyback authorization. I mean, I think there is obviously a much larger authorization that you guys have done in the past. I think people are happy to see that. How should we think about the timing of that going forward, but, you know, in the past you guys have done pretty measured buybacks over time? Should we expect this one to occur anymore quickly than the others or is it going to kind of picking you to be at the same pace as the others described larger overall authorization?

I think you’ve somewhat characterized how we have pushed it. We’ve not been mechanical. We’ve been very thoughtful about what we’ve done and we’ll continue to be thoughtful. So, you shouldn’t look for any particular standard pattern, if you will. We’ll look for the right opportunity to buyback over time.

Okay. Thanks very much.

Okay. Next, we will go to the line of David Roman with Goldman Sachs. Please go ahead. David Roman – Goldman Sachs: Good afternoon. Thank you for taking the question. I was hoping you could talk a little bit more about any efforts you are undertaking or look to undertake to address the weakness in the dVH? I mean obviously, the seasonal piece and macro dynamics are what they are, but maybe any sort of impact you’ve had from the recent noise in the marketplace? What is your plan to sort of start to stem that? And then how long do you think it might take before we start to see some positive return from those efforts?

On the first comment of what do we think there is in terms of an opportunity in our dVH? First of all, we look out and say often procedures that are still being done through a laparotomy are great opportunity for us. We look around the country to see where those are and our ability to serve those patients. That’s our primary opportunity. You implied in your discussion that the negative press is having a fair impact in this. It’s not clear but that’s true. Right now separating out how much of this is seasonality. How much is just a total inpatient admission, and how much is specific going to it’s actually a hard think to piece apart. Having said that, I think the strength of da Vinci Surgery has been in its clinical outcomes and so that’s where we start relative to open surgery both in the publications and in the education of our sales team and the interaction with hospitals it’s that sort of data, and so we’ve done that and we’ll continue to do that in terms of supplying them the data and the resources they need to approach those patients. David Roman – Goldman Sachs: That’s helpful. And then I know a lot of the questions on this call regarding the market recent noise and marketplace concerns have been focused on gynecology, but it is fair to say that hasn’t sort of trickled into the other parts you’ve been in some of the newer categories like general surgery that continued to be fairly robust and your ability to attract new users, train new users, I mean any change in sort of your size of your training classes interest level I mean any other metrics that you could help us to gauge this sort of looming question around noise versus reality?

We have not seen a change in that is our for people be trained and we haven’t seen anything that I can point to in the general surgery marketplace that would indicate a real impact?

Yeah, and again I think evidence of that that we have that helps us make that statement or the actual procedure numbers, the number of people who are accessing proctors and training. And just as a level set, GYN if you look at things like Sacrocolpopexy and Myomectomy and Endometriosis Resection. If GYN is end hysterectomy for malignant conditions, this is a very robust category and while dVH Benign is certainly the largest individual segment of that category, as we look out overall at GYN, we’ve remain very encouraged. David Roman – Goldman Sachs: Okay, and maybe the last question just a follow-up on the share repurchase authorization. You’ve in the past I think you’ve got to use share repurchase to kind of offset the impact of options being exercised and that sort of been not a top use of cash, but sort of something that you’ve done to manage options, dilution. Is there anything different are there prioritization to think about this $1 billion authorization or it’s just the cash balance has got into where it is the stock price is where it is that you need more to offset the impact of options exercised?

I think number one is in the authorization reflected confidence in the business, but I think that it’s also intended to be a return to shareholders. We’re talking about a $1 billion set more than offset any stock option dilution that we create during the year. David Roman – Goldman Sachs: Okay, got it. Thank you very much.

Our next question today comes from the line of Larry Keusch. Please go ahead. Lawrence Keusch – Raymond James Financial: Gary, there has been obviously a lot of discussion focused on procedures and the impact from the predicts over last several months, but I’m wondering if we can perhaps shift towards system sales obviously quite strong this quarter, but I’m wondering if you’re seeing anything change in the selling cycle or there has been some speculation that hospitals may holdback on purchasing while there is all those noise out there, so any color would be helpful?

All I can speak to is the first quarter and looking at the first quarter we haven’t seen any meaningful impact of negative press on capital sales. In fact, the capital side was pretty strong as you mentioned not only in systems as a whole, but and the attachment of some of the products we’ve added to assign. So, dual console sale, simulator sales, Firefly demand have continued to be strong, again don’t have a crystal ball is to what happens in the future, but so far the conversations have been pretty straightforward. Lawrence Keusch – Raymond James Financial: Okay, great. And then this is also come up over the last several calls, you’ve expressed some need to work on the European organization, so I’m just curious kind of take your temperature little bit on where we are in that process?

I think that we’ve been making on a good progress, I think that it’s been measured, but we’ve been adding resources in a few places, some of that has been leadership resources, some of that has been people in the sales force experienced, people into the sales force and some of it is in areas such as regulatory and reimbursement, we’ve made some great hires there they are integrating well and as we’ve said in the past this is something that will happen over quarters not over days, but we are pleased with our partners. Lawrence Keusch – Raymond James Financial: Okay. And then lastly, just on the usage of cash obviously, share repurchase remains out there, but what are the latest thoughts around potentially using cash for some M&A opportunities?

Go ahead.

So, I think there is, our eyes are always open for opportunities for a few things and some of it has been as you know on the past looking for technologies that we think did really well with robotic surgery and advancing the ability of surgeons and the systems to do more. We continue to be looking forward and able to acquire those things, we think make a difference. We also think that investments in markets not in the United States are really important. You’ve seen this through that in the past. And we continue to do so in terms of investing into existing organizational frameworks in Japan and in Korea and also positioning ourselves for success in other markets or U.S. having cash help us to do that as well. Lawrence Keusch – Raymond James Financial: Okay, terrific. Thank you.

And we have a question from the line of David Lewis with Morgan Stanley. Please go ahead. Jonathan Demchick – Morgan Stanley: Hello, this is actually Jon in for David. So, we had a few questions. One just while procedures were a bit slower than expected, instrument revenue is still strong and I guess that was more related to the revenue per procedure being higher. And I’m just wondering if you could maybe break that out and how much of that was related to stocking whereas how much of that was some of the more advanced tools? You mentioned thoughts on the system ASP is to normalize down a bit, any thoughts to where revenue procedure should go throughout the year?

We’ve actually seen a bit of an uptick in the base, what we call the base. And so if you parse out the stocking orders associated with new system purchases, we see a little uptick in the base and that reflects the new products. So that reflects usage of Firefly, usage of vessel sealing. And so, I think it was also benefited, the quarter was also benefited by the timing of purchases of buying through distributors and other customers where they’re entering their new fiscal year and so they may have bought more. And so I think there is a little bit higher than maybe we would expect going forward, but it’s definitely being benefited by the new products.

And we’ve always talked there is a lot of moving parts in this overall instrument and accessory per procedure. We have talked in the past about a natural trend downward as the impact of stocking orders becomes less on our larger installed base and procedure mix moving towards the simpler mix maybe moving downwards but now, what we’re seeing, the impact of the new products, even beyond the initial stocking of the new products which we’ve talked before. We’re talking about utilization of products like the Vessel Sealer and the Firefly in procedures, which getting those procedures utilized and those products used in procedures. It’s allowing us to really to capture larger portion of the hospitals procedure spend through the da Vinci platform. And so directionally, we probably see that winning the day at least for the balance of this year. Jonathan Demchick – Morgan Stanley: Thank you. That’s very helpful. And then a quick follow-up on Single-Site chole. First, I was more curious to, if you could break out how much Single-Site chole is out of our chole is? And then also it just seen kept increased each year on the Single-Site side, and I was wondering if you can maybe discuss how much of those are VP buyers, how much of those are new adaptors and just what you’ve seen there?

Yeah. At this point in time, the Single-Site chole, it’s really moving from an initial introduction into more key element of our business here, a lot more matured status. We’ve talked about the number of customers who bought Single-Site products. We may move away from that. I think as it becomes part of the norm, the portion that’s Single-Site versus multi-port that’s always transitioning as most people are aware the multi-port side is generally part of the training pathway to move towards single port, but I think the multi-port side is really the stat as an avenue to move towards the ultimate destination of the single port. So it’s probably not as important at that point, at any of time of how many of those are.

Just a qualitative remark on the reorder rate. We have been watching and we’ve been pleased so far. Reorder rate has been positive for us. Jonathan Demchick – Morgan Stanley: Okay, thank you very much.

Okay. Next from the line of (inaudible) with SunTrust. Please go ahead.

Thanks very much. I thought maybe I would first ask about Single-Site for dVH. I think I was a little bit surprised in kind of thinking back in your traction with Single-Site for chole and what that did in 2012, essentially its first year. In your comments that you thought it might not have much of an impact this year. So I thought maybe you could explain the differences between the rollout here versus the rollout for chole’s and why it’s going to take a little bit longer?

Well, again, as you know, I mean, we’re pretty measured in our approach with all of these various procedures. And I think when you look at Single incision hysterectomy, you’re looking at products that are required to be made which we’re doing and then we know how to do that. And then you’re looking at really understanding, the physicians are looking at really understanding procedure choreography, how do I do this, how do I do that, how do I close the cup, how do I take the next et cetera. And so, it’s difficult to try to assign a reasonable timeline to how the choreography will go, in addition to the general issues of manufacturing new products getting new supply chain down et cetera. So we’re being pretty cautious about that. Now, if it turns out that that changes in time will certainly let you know. But I think there is a, I think there are number of surveys that people have done and we’ve done ourselves, where there is a real excitement for from the customer. And so we just want to make sure, do you take this into consideration and that work that into your expectations because it’s really too early to call.

All right, okay. And then on the system side, just the comment you made about system mix in ASPs maybe not holding through the whole year. I’m just wondering, if that’s more product mix related or is that geography related? And if it’s on a product side just specifically what you’re thinking in terms of the products that might not be relating the year that you’ve been selling.

Yeah, it’s primarily product mix and we had 48 of the 164 units were dual console systems in the first quarter and that’s by far in a way the highest proportion that we’ve had. We’d see that attach rate returning to more historical levels and as such the ASP. It’d be less than we saw here in the first quarter, maybe more in line with what we saw throughout 2012.

Okay. And then last one from me, I realized that with regard to the FDA MedSun survey, I guess there was only nine people or so may be it’s not even a survey or definitely not a government probe, it’s may be some would call it. But have you guys had talked to any of the doctors involved in that kind of inquiry or do you know anything about the reports that might be coming out or what you might be anticipating?

As far as we know it was a confidentially run survey and so we have no, nothing to share on that front.

Okay, thanks very much guys.

All right, we have time for one more question.

Our final question today will come from the line of Rick [Wise] with Stifel. Please go ahead. Miroslava Minkova – Stifel Nicolaus: Hi, it’s actually Miroslava for Rick today. Let me start with asking a question on Japan could not [help] but note of the significant number of systems you played there this quarter and it was coincided with the Si approval in Japan. Was the Si what you needed to help unlock this market to some extent? And related to that should we expect this kind of rate to continue or was this, do you view this is as an anomaly as you launch the Si?

I think that they were happy to get a Si approval and I think it’s been well received. I think that there is some amount of early excitement having to do with Si long-term as you look at that market. Procedure reimbursement is going to be the thing that is the long and sustained growth path. And so I think system sales in Japan are going to be lumpy, until additional procedures are reimbursed. And that’s something that we’re working with the surgical societies on supporting and helping them to complete that activity. Miroslava Minkova – Stifel Nicolaus: Okay, and…

One last question please. Miroslava Minkova – Stifel Nicolaus: And going back to just the both concerted effort by the critics of surgery. I was wondering if you have any plans to highlight some of your data on the outcomes and perhaps the economics of your procedures. And it goes back to what was asked earlier, but maybe if I could ask it a little bit differently has your conversation with your customers changed in any way as a result of the negative press?

It was two questions. On the first one, do we have plans to share our data? Yes, we do. And we have been and we will continue to do so. In terms of the conversations that occur with customers over this and in essence the conversations with customers are amongst the most straightforward because they understand the issues on all sides. The conversations really come down to their own experiences and the data and we’re happy to and well, condition well positioned to have those conversations. We’ll continue to do so. And as additional data comes out, we were happy to share with. Miroslava Minkova – Stifel Nicolaus: Okay, thank you.

That was our last question. In closing, da Vinci Surgery has proven safety, efficacy, economic and ergonomic benefits when compared to the open surgical procedures, it is replacing. We are steadfast in our conviction in the value that da Vinci has and will bring to medicine. And we thank you for your support and helping Intuitive expand the benefits of minimally invasive surgery. We’ll look forward to speaking to you again in three months.

Ladies and gentlemen that does conclude our conference for today. Thank you for your participation and using the AT&T executive teleconference. You may now disconnect.